Allarity Therapeutics Strengthens Leadership for Cancer Programs

Allarity Therapeutics, Inc. ( (ALLR) ) has issued an announcement.

Allarity Therapeutics, a clinical-stage pharmaceutical company, has bolstered its leadership with the appointment of Jeremy R. Graff, Ph.D., as President and Chief Development Officer to guide its clinical development programs, such as the stenoparib PARP inhibitor program. Dr. Graff, an experienced biotech and pharma industry veteran with a focus on cancer therapies, is joined by Jose Iglesias, M.D., as Consultant Chief Medical Officer, and Jesper Høiland as a Strategic Advisor to enhance the company’s strategic and clinical endeavors, signaling a strong move toward advancing personalized cancer treatments.

Find detailed analytics on ALLR stock on TipRanks’ Stock Analysis page.